Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms. Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions.
Company Details
- Founded
- 2001
- Address
- Burlingame, California
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.humanigen.com/
- HQ
- Burlingame, California
Humanigen, Inc. Questions
Humanigen, Inc.'s website is https://www.humanigen.com/
Humanigen, Inc.'s LinkedIn profile is https://www.linkedin.com/company/humanigen-inc
Humanigen, Inc.'s industry is
Pharmaceutical Manufacturing
Humanigen, Inc.'s top competitors are
Humanigen,
Alcyone Therapeutics Inc.,
Bexion Pharmaceuticals,
Spineovations, Inc.,
Propedix Inc,
Essa Pharma,
Pdc Biopharma,
Shanghai Junshi Biosciences Co Ltd,
Vivoryon Therapeutics N.v.,
Lexicon Pharmaceuticals, Inc..
Humanigen, Inc.'s categories are Pharmaceutical Manufacturing
Humanigen, Inc.'s founding year is 2001
